ncRNA basic information
ncRNA ID:
MI0003130
ncRNA Database:
miRBase
ncRNA Name:
miR-202
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
qRT-PCR
ncRNA Target Gene:
KRas
ncRNA Pathway:
Ras/MAPK Pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00515 (APRD00359)
Drug Name:
Cisplatin
Drug Method:
Quantitative reverse transcriptase real-time PCR analysis was performed to examine the expression of miR-202. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were performed to evaluate the sensitivity of cisplatin against NSCLC cells. The miR-202/KRas axis was confirmed by western blot and luciferase reporter assays. Cell apoptosis was measured by flow cytometry. KRas expression, MEK1/2 and ERK1/2 phosphorylation, and activation of caspase-9 and caspase-3 were detected by western blot.
Drug Response:
sensitive
Cancer basic information
Cancer:
lung non-small cell carcinoma
Tissue/Cell:
cell line (NCI-H441 and A549)
Other information
Title:
miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Journal:
Cell Physiol Biochem
Published:
2018
PubMed ID:
30522099